Eli Lilly and Company (WKN: 858560) LLY

Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound.
Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.
Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges.
Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion.


weiter  hier:
https://investor.lilly.com/news-releases/...025-financial-results-and

 

Die sonst so erfolgsverwöhnte Eli Lilly-Aktie kam zuletzt an der Börse mächtig unter die Räder. In den letzten vier Wochen ging es mit dem Pharmatitel um gut -20% bergab. Kaufen Anleger dem US-Pharmakonzern seine Adipositas-Wachstumsgeschichte nicht mehr ab?
https://www.finanznachrichten.de/...wachstumsstory-nicht-mehr-486.htm